Articles tagged with Wiskott Aldrich Syndrome
A novel autologous gene therapy for Wiskott-Aldrich syndrome has demonstrated durable clinical benefits in a phase 3 study, with 96% survival at 1 and 5 years. The treatment, etu-cel, has also reduced severe infections and moderate-to-severe bleeding events.
Waskyra, an ex vivo gene therapy, offers new hope for patients with Wiskott-Aldrich syndrome by reducing severe bleeding events and serious infections. The FDA approval confirms Fondazione Telethon's excellence in rare genetic disease research.
Fondazione Telethon's gene therapy Waskyra, treating Wiskott-Aldrich Syndrome, has received CHMP positive opinion and marketing authorisation in the European Union. The therapy offers new hope for patients affected by this rare genetic disorder.
Researchers at the Salk Institute discovered that genetic mutations disrupt RNA splicing in Wiskott-Aldrich syndrome, leading to bleeding and immune deficiencies. This finding suggests new targets for treatment with small molecule drugs and sheds light on the basic biology of RNA splicing.
Researchers have created stem cell models that mimic the genetic disorder, revealing the role of WASP protein in regulating RNA splicing and finding potential therapeutic targets. These findings could lead to new treatments for Wiskott-Aldrich syndrome, a devastating immune deficiency disorder.
A study published in JAMA found that gene therapy resulted in clinical improvement for children with Wiskott-Aldrich syndrome, a rare immunodeficiency disorder. The treatment, which involved infusing corrected stem cells back into patients, led to the resolution of severe eczema and recurring infections.
Gene therapy vectors derived from HIV successfully treat metachromatic leukodystrophy and Wiskott-Aldrich syndrome, restoring missing protein and reversing neurodegenerative process. The treatment is safe and effective, offering hope for patients with severe genetic diseases.
The NIH is expanding its Rare Diseases Clinical Research Network with a new $117 million funding round. The network aims to understand the natural history, epidemiology, diagnosis, and treatment of over 95 rare diseases through clinical studies involving more than 5,000 patients.
Notch signaling plays a crucial role in determining cell fate in fruit flies. A study found that mutations in the WASp gene affect T-cell function, leading to Wiskott-Aldrich syndrome. The researchers suggest that defects in Delta presentation could explain the loss and dysfunction of T-cells in patients with the disorder.